Gyre Therapeutics (GYRE) Assets Average (2011 - 2026)

Gyre Therapeutics (GYRE) has 16 years of Assets Average data on file, last reported at $164.1 million in Q1 2026.

• Assets Average for Q1 2026 came in at $164.1 million, up 28.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $164.1 million (up 28.59% YoY), and the FY2025 annual result was $145.8 million, up 20.5% from the prior year.
• Assets Average improved to $164.1 million in Q1 2026 per GYRE's latest filing, from $162.8 million in the prior quarter.
• Over five years, Assets Average peaked at $164.1 million in Q1 2026 and troughed at $11.2 million in Q3 2023.
• A 5-year average of $94.6 million and a median of $119.3 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2024: Assets Average plunged 80.45% in 2023, then soared 1001.03% in 2024.
• A 5-year view of Assets Average shows it stood at $57.9 million in 2022, then gained by 9.27% to $63.3 million in 2023, then soared by 98.13% to $125.3 million in 2024, then rose by 29.87% to $162.8 million in 2025, then gained by 0.81% to $164.1 million in 2026.
• Business Quant data shows GYRE's Assets Average at $164.1 million in Q1 2026, $162.8 million in Q4 2025, and $156.0 million in Q3 2025.